IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies
Status:
Completed
Trial end date:
2018-12-12
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open label study of the dose and duration of an orally administered LSD1
inhibitor, IMG-7289, in patients with acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known
as tretinoin and Vesanoid®) in combination with IMG-7289. This study investigates the
following:
- The safety and tolerability of IMG-7289, with and without ATRA
- The pharmacodynamic effect of different IMG-7289 doses and treatment durations, as well
as IMG-7289 administered in combination with ATRA
- The pharmacokinetics of IMG-2789, with and without ATRA